Published in DNA Cell Biol on January 01, 2007
Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev (2008) 2.74
Rb regulates fate choice and lineage commitment in vivo. Nature (2010) 2.60
Rising from the RecQ-age: the role of human RecQ helicases in genome maintenance. Trends Biochem Sci (2008) 2.24
Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res (2008) 2.18
Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest (2009) 2.09
Mouse fibroblasts lacking RB1 function form spheres and undergo reprogramming to a cancer stem cell phenotype. Cell Stem Cell (2009) 2.00
Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc Natl Acad Sci U S A (2008) 1.98
Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS One (2008) 1.90
Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. Clin Exp Metastasis (2011) 1.68
Targeting the osteosarcoma cancer stem cell. J Orthop Surg Res (2010) 1.52
Identification of Differentially Expressed MicroRNAs in Osteosarcoma. Sarcoma (2011) 1.48
MicroRNA Involvement in Osteosarcoma. Sarcoma (2012) 1.38
Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci U S A (2014) 1.36
Perturbation of 14q32 miRNAs-cMYC gene network in osteosarcoma. Bone (2011) 1.31
A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis. Nat Genet (2015) 1.23
High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/β-catenin target gene, CDC25A. Cancer Cell (2011) 1.22
The Role of RUNX2 in Osteosarcoma Oncogenesis. Sarcoma (2010) 1.18
Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics. PLoS One (2009) 1.15
MicroRNAs at the human 14q32 locus have prognostic significance in osteosarcoma. Orphanet J Rare Dis (2013) 1.13
Elevated expression of Runx2 as a key parameter in the etiology of osteosarcoma. Mol Biol Rep (2008) 1.09
Genetically transforming human mesenchymal stem cells to sarcomas: changes in cellular phenotype and multilineage differentiation potential. Cancer (2009) 1.08
Minnelide reduces tumor burden in preclinical models of osteosarcoma. Cancer Lett (2013) 1.07
Influence of genetic background on tumor karyotypes: evidence for breed-associated cytogenetic aberrations in canine appendicular osteosarcoma. Chromosome Res (2009) 1.07
Increased expression of lncRNA HULC indicates a poor prognosis and promotes cell metastasis in osteosarcoma. Int J Clin Exp Pathol (2015) 1.07
A new approach for prediction of tumor sensitivity to targeted drugs based on functional data. BMC Bioinformatics (2013) 1.05
Long non-coding RNA HOTTIP is up-regulated and associated with poor prognosis in patients with osteosarcoma. Int J Clin Exp Pathol (2015) 1.05
A review of the association between osteosarcoma metastasis and protein translation. J Comp Pathol (2012) 1.04
Combinatorial treatment of DNA and chromatin-modifying drugs cause cell death in human and canine osteosarcoma cell lines. PLoS One (2012) 1.03
MicroRNA-34c inversely couples the biological functions of the runt-related transcription factor RUNX2 and the tumor suppressor p53 in osteosarcoma. J Biol Chem (2013) 1.01
A comprehensive candidate gene approach identifies genetic variation associated with osteosarcoma. BMC Cancer (2011) 1.00
NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma. Oncogene (2015) 0.99
Defective osteogenic differentiation in the development of osteosarcoma. Sarcoma (2011) 0.98
BMP-2 inhibits the tumorigenicity of cancer stem cells in human osteosarcoma OS99-1 cell line. Cancer Biol Ther (2011) 0.98
Decitabine-induced demethylation of 5' CpG island in GADD45A leads to apoptosis in osteosarcoma cells. Neoplasia (2008) 0.95
The cancer-related Runx2 protein enhances cell growth and responses to androgen and TGFbeta in prostate cancer cells. J Cell Biochem (2010) 0.94
The ARF tumor suppressor regulates bone remodeling and osteosarcoma development in mice. PLoS One (2010) 0.93
Immune response to RB1-regulated senescence limits radiation-induced osteosarcoma formation. J Clin Invest (2013) 0.92
Cell cycle related modulations in Runx2 protein levels are independent of lymphocyte enhancer-binding factor 1 (Lef1) in proliferating osteoblasts. J Mol Histol (2007) 0.92
Cyclin E1 is amplified and overexpressed in osteosarcoma. J Mol Diagn (2011) 0.91
FHL2 silencing reduces Wnt signaling and osteosarcoma tumorigenesis in vitro and in vivo. PLoS One (2013) 0.91
Epigenetic remodeling of chromatin architecture: exploring tumor differentiation therapies in mesenchymal stem cells and sarcomas. Curr Stem Cell Res Ther (2010) 0.90
Osteosarcoma models: from cell lines to zebrafish. Sarcoma (2012) 0.87
Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery. Br J Cancer (2013) 0.87
Molecular alterations associated with osteosarcoma development. Sarcoma (2012) 0.86
MicroRNA-199a-3p and microRNA-34a regulate apoptosis in human osteosarcoma cells. Biosci Rep (2014) 0.85
The tankyrase-specific inhibitor JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines. Cancer Med (2013) 0.83
Pivotal regulatory network and genes in osteosarcoma. Arch Med Sci (2012) 0.83
Primary neoplasms of bones in mice: retrospective study and review of literature. Vet Pathol (2011) 0.83
Bilateral synchronous tibial periosteal osteosarcoma with familial incidence. Skeletal Radiol (2012) 0.82
Prognostic significance of HLA EMR8-5 immunohistochemically analyzed expression in osteosarcoma. Diagn Pathol (2014) 0.82
MiR-26a inhibits stem cell-like phenotype and tumor growth of osteosarcoma by targeting Jagged1. Oncogene (2016) 0.82
MiR-29b suppresses the proliferation and migration of osteosarcoma cells by targeting CDK6. Protein Cell (2016) 0.81
A systems biology approach to identify molecular pathways altered by HDAC inhibition in osteosarcoma. J Cell Biochem (2012) 0.81
Osteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate Therapies. Crit Rev Oncog (2015) 0.81
Involvement of PAR-4 in cannabinoid-dependent sensitization of osteosarcoma cells to TRAIL-induced apoptosis. Int J Biol Sci (2014) 0.80
The prognostic significance of Src and p-Src expression in patients with osteosarcoma. Med Sci Monit (2015) 0.80
Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy. Nat Rev Endocrinol (2017) 0.80
The Forkhead Transcription Factor FOXP2 Is Required for Regulation of p21WAF1/CIP1 in 143B Osteosarcoma Cell Growth Arrest. PLoS One (2015) 0.79
Case-parent analysis of variation in pubertal hormone genes and pediatric osteosarcoma: a Children's Oncology Group (COG) study. Int J Mol Epidemiol Genet (2012) 0.79
Increased miR-155-5p and reduced miR-148a-3p contribute to the suppression of osteosarcoma cell death. Oncogene (2016) 0.79
Expression and clinical significance of cyclooxygenase-2 and microRNA-143 in osteosarcoma. Exp Ther Med (2015) 0.79
The Current and Future Therapies for Human Osteosarcoma. Curr Cancer Ther Rev (2013) 0.79
A New Paradigm to Mitigate Osteosarcoma by Regulation of MicroRNAs and Suppression of the NF-κB Signaling Cascade. Balsaenggwa Saengsig (2014) 0.79
Osteotropic cancer diagnosis by an osteocalcin inspired molecular imaging mimetic. Biochim Biophys Acta (2013) 0.78
Sustained Low-Dose Treatment with the Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma Cells. Sarcoma (2013) 0.78
MicroRNA-33a-5p suppresses growth of osteosarcoma cells and is downregulated in human osteosarcoma. Oncol Lett (2015) 0.78
Progression of Osteosarcoma from a Non-Metastatic to a Metastatic Phenotype Is Causally Associated with Activation of an Autocrine and Paracrine uPA Axis. PLoS One (2015) 0.77
Transcription factor Snai1-1 induces osteosarcoma invasion and metastasis by inhibiting E-cadherin expression. Oncol Lett (2014) 0.77
β-Catenin Does Not Confer Tumorigenicity When Introduced into Partially Transformed Human Mesenchymal Stem Cells. Sarcoma (2012) 0.76
Nanomedicine applications in orthopedic medicine: state of the art. Int J Nanomedicine (2015) 0.76
Research findings working with the p53 and Rb1 targeted osteosarcoma mouse model. Am J Cancer Res (2014) 0.75
Heterotypic mouse models of canine osteosarcoma recapitulate tumor heterogeneity and biological behavior. Dis Model Mech (2016) 0.75
The immunotherapy of canine osteosarcoma: a historical and systematic review. J Vet Intern Med (2015) 0.75
Protein kinase C epsilon and genetic networks in osteosarcoma metastasis. Cancers (Basel) (2013) 0.75
Long non-coding RNA AK093407 promotes proliferation and inhibits apoptosis of human osteosarcoma cells via STAT3 activation. Am J Cancer Res (2017) 0.75
Network analysis of microRNAs and genes in human osteosarcoma. Exp Ther Med (2015) 0.75
Proteomic technologies for the study of osteosarcoma. Sarcoma (2012) 0.75
Ameloblastin induces tumor suppressive phenotype and enhances chemosensitivity to doxorubicin via Src-Stat3 inactivation in osteosarcoma. Sci Rep (2017) 0.75
Osteosarcoma With Apparent Ewing Sarcoma Gene Rearrangement. J Pediatr Hematol Oncol (2016) 0.75
Invertible micellar polymer nanoassemblies target bone tumor cells but not normal osteoblast cells. Future Sci OA (2015) 0.75
Nanotechnology in orthopedics. J Orthop (2016) 0.75
The Hippo pathway and human cancer. Nat Rev Cancer (2013) 5.17
High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer (2006) 2.97
Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res (2012) 2.46
Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet (2013) 2.21
Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest (2009) 2.09
FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov (2012) 1.83
RECK--a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer Metastasis Rev (2007) 1.57
Liposarcoma: molecular genetics and therapeutics. Sarcoma (2010) 1.55
Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing. BMC Med Genomics (2014) 1.53
Stress-induced cellular adaptive strategies: ancient evolutionarily conserved programs as new anticancer therapeutic targets. Bioessays (2014) 1.40
Differential tissue distribution of tryptophan hydroxylase isoforms 1 and 2 as revealed with monospecific antibodies. Brain Res (2006) 1.27
Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis. Clin Cancer Res (2010) 1.26
Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. Am J Pathol (2005) 1.26
Impaired bone development and increased mesenchymal progenitor cells in calvaria of RB1-/- mice. Proc Natl Acad Sci U S A (2008) 1.22
Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. J Clin Oncol (2013) 1.21
Dopamine quinones activate microglia and induce a neurotoxic gene expression profile: relationship to methamphetamine-induced nerve ending damage. Ann N Y Acad Sci (2006) 1.15
Mephedrone, an abused psychoactive component of 'bath salts' and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum. J Neurochem (2012) 1.13
HES1 cooperates with pRb to activate RUNX2-dependent transcription. J Bone Miner Res (2006) 1.12
PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer (2006) 1.11
Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials. J Clin Oncol (2011) 1.07
The relationship between unmet needs and distress amongst young people with cancer. Support Care Cancer (2011) 1.04
An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. Cancer Res (2005) 1.02
Genetic depletion of brain 5HT reveals a common molecular pathway mediating compulsivity and impulsivity. J Neurochem (2012) 1.01
Parathyroid hormone-related protein protects against mammary tumor emergence and is associated with monocyte infiltration in ductal carcinoma in situ. Cancer Res (2009) 0.99
Mephedrone does not damage dopamine nerve endings of the striatum, but enhances the neurotoxicity of methamphetamine, amphetamine, and MDMA. J Neurochem (2013) 0.96
Gender-specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthood. Int J Cancer (2009) 0.94
Next-generation sequence analysis of cancer xenograft models. PLoS One (2013) 0.94
Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours. Clin Sarcoma Res (2012) 0.94
Immune response to RB1-regulated senescence limits radiation-induced osteosarcoma formation. J Clin Invest (2013) 0.92
Cyclin E1 is amplified and overexpressed in osteosarcoma. J Mol Diagn (2011) 0.91
Dopamine disposition in the presynaptic process regulates the severity of methamphetamine-induced neurotoxicity. Ann N Y Acad Sci (2008) 0.87
High frequency of germline TP53 mutations in a prospective adult-onset sarcoma cohort. PLoS One (2013) 0.85
Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer. BMC Cancer (2011) 0.85
Soman increases neuronal COX-2 levels: possible link between seizures and protracted neuronal damage. Neurotoxicology (2010) 0.84
Cancer-associated neochromosomes: a novel mechanism of oncogenesis. Bioessays (2009) 0.83
Prevailing importance of the hedgehog signaling pathway and the potential for treatment advancement in sarcoma. Pharmacol Ther (2012) 0.83
Nucleus accumbens invulnerability to methamphetamine neurotoxicity. ILAR J (2011) 0.82
Targeting the p53 Pathway in Ewing Sarcoma. Sarcoma (2010) 0.82
The oncogenic properties of EWS/WT1 of desmoplastic small round cell tumors are unmasked by loss of p53 in murine embryonic fibroblasts. BMC Cancer (2013) 0.81
RECK in osteosarcoma: a novel role in tumour vasculature and inhibition of tumorigenesis in an orthotopic model. Cancer (2011) 0.81
A role for alphaV integrin subunit in TGF-beta-stimulated osteoclastogenesis. Biochem Biophys Res Commun (2003) 0.80
Novel approaches to treatment of leiomyosarcomas. Curr Oncol Rep (2011) 0.80
Intra-patient dose escalation in Ewing's sarcoma treated with vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide: a retrospective review. Clin Sarcoma Res (2013) 0.80
Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling. Cancer Res (2013) 0.80
Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: findings from the Adjuvant Colon Cancer Endpoints data set. J Clin Oncol (2012) 0.79
The attitudes of people with sarcoma and their family towards genomics and incidental information arising from genetic research. Clin Sarcoma Res (2013) 0.79
Regulation of fetal versus embryonic gamma globin genes: appropriate developmental stage expression patterns in the presence of HS2 of the locus control region. Blood (2002) 0.79
A newly characterized human well-differentiated liposarcoma cell line contains amplifications of the 12q12-21 and 10p11-14 regions. Virchows Arch (2012) 0.78
Surveillance recommendations for patients with germline TP53 mutations. Curr Opin Oncol (2015) 0.78
Other targetable sarcomas. Semin Oncol (2009) 0.78
Sustained Low-Dose Treatment with the Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma Cells. Sarcoma (2013) 0.78
Studying the role of the immune system on the antitumor activity of a Hedgehog inhibitor against murine osteosarcoma. Oncoimmunology (2012) 0.78
The promise of PET in clinical management and as a sensitive test for drug cytotoxicity in sarcomas. Expert Rev Mol Diagn (2008) 0.78
Use of ketamine for ischemic pain in end-stage renal failure. J Pain Symptom Manage (2008) 0.76
Multiomics medicine in oncology: assessing effectiveness, cost-effectiveness and future research priorities for the molecularly unique individual. Pharmacogenomics (2013) 0.75
Behavioral and neurochemical effects of repeated MDMA administration during late adolescence in the rat. Prog Neuropsychopharmacol Biol Psychiatry (2013) 0.75
The hard and soft sides of cancer programming. Bioessays (2010) 0.75
Tobacco smoke modulates ozone-induced toxicity in rat lungs and central nervous system. Inhal Toxicol (2013) 0.75
Molecular profiling of non-small cell lung cancer: of what value in clinical practice? Heart Lung Circ (2008) 0.75